Log in

NYSE:ORGSOrgenesis Stock Price, Forecast & News

$5.56
+0.11 (+2.02 %)
(As of 08/5/2020 04:00 PM ET)
Add
Compare
Today's Range
$5.46
Now: $5.56
$5.62
50-Day Range
$5.40
MA: $6.01
$6.99
52-Week Range
$2.35
Now: $5.56
$8.20
Volume24,701 shs
Average Volume106,333 shs
Market Capitalization$122.30 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Orgenesis Inc., a service and research company, focus on the development and manufacture of cell therapy for advanced medicinal products in the field of regenerative medicine industry. It operates through two segments, Contract Development and Manufacturing Organizations (CDMO) and Cellular Therapy (CT) Business. The CDMO segment specializes in cell therapy development for advanced medicinal products. This segment provides process and assay development services; and current Good Manufacturing Practices contract manufacturing services. The CT Business segment develops cell trans-differentiation technology induce shift in the developmental fate of cells from the liver and differentiating them into pancreatic beta cell-like insulin producing cells for patients with Type 1 diabetes. The company has a collaboration agreement with CureCell Co., Ltd. to carry out pre-clinical and clinical activities related to the commercialization of autologous insulin producing cell therapy product in Korea; and with BGN Technologies and the National Institute for Biotechnology to develop and commercialize a scaffold technology for cell transplantation, as well as a collaboration and license agreement with Mircod Limited for the research, development, and commercialization of various technologies related to biological sensing for Orgenesis's clinical development and manufacturing projects. It also has a collaboration agreements with Ben-Gurion University and MangoGen Pharma Inc. The company was formerly known as Business Outsourcing Services, Inc. and changed its name to Orgenesis Inc. in August 2011. Orgenesis Inc. was founded in 2008 and is based in Germantown, Maryland.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 0.0Community Rank: 2.2Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

0.44 out of 5 stars


Industry, Sector and Symbol

Industry Biotechnology
Sub-IndustryN/A
SectorMedical
CUSIPN/A
CIKN/A
Phone480-659-6404

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

EmployeesN/A
Market Cap$122.30 million
Next Earnings DateN/A
OptionableNot Optionable
$5.56
+0.11 (+2.02 %)
(As of 08/5/2020 04:00 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive ORGS News and Ratings via Email

Sign-up to receive the latest news and ratings for ORGS and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Orgenesis (NYSE:ORGS) Frequently Asked Questions

How has Orgenesis' stock been impacted by COVID-19 (Coronavirus)?

Orgenesis' stock was trading at $3.86 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, ORGS shares have increased by 44.0% and is now trading at $5.56.
View which stocks have been most impacted by Coronavirus
.

How were Orgenesis' earnings last quarter?

Orgenesis Inc. (NYSE:ORGS) announced its quarterly earnings data on Monday, May, 11th. The company reported ($0.39) earnings per share (EPS) for the quarter. The firm had revenue of $1.88 million for the quarter.
View Orgenesis' earnings history
.

Has Orgenesis been receiving favorable news coverage?

Media coverage about ORGS stock has been trending somewhat negative this week, according to InfoTrie Sentiment. InfoTrie rates the sentiment of media coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. Orgenesis earned a media sentiment score of -1.4 on InfoTrie's scale. They also gave news articles about the company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an effect on the company's share price in the near future.
View the latest news about Orgenesis
.

Who are some of Orgenesis' key competitors?

What other stocks do shareholders of Orgenesis own?

Who are Orgenesis' key executives?

Orgenesis' management team includes the following people:
  • Ms. Vered Caplan, Chairman, CEO & Pres (Age 49)
  • Prof. Sarah Ferber, Founder & Chief Scientific Officer (Age 64)
  • Mr. Neil T. Reithinger, CFO, Sec. & Treasurer (Age 48)
  • Dr. Denis Bedoret, Gen. Mang. of MaSTHERCELL (Age 37)

What is Orgenesis' stock symbol?

Orgenesis trades on the New York Stock Exchange (NYSE) under the ticker symbol "ORGS."

How do I buy shares of Orgenesis?

Shares of ORGS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Orgenesis' stock price today?

One share of ORGS stock can currently be purchased for approximately $5.56.

How big of a company is Orgenesis?

Orgenesis has a market capitalization of $122.30 million.

What is Orgenesis' official website?

The official website for Orgenesis is www.orgenesis.com.

How can I contact Orgenesis?

The company can be reached via phone at 480-659-6404.

This page was last updated on 8/6/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.